Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2011 1
2012 1
2013 11
2014 7
2015 7
2016 4
2017 3
2018 5
2019 2
2020 7
2021 8
2022 6
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. Among authors: qiu w. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.
Qin S, Li J, Wang L, Xu J, Cheng Y, Bai Y, Li W, Xu N, Lin LZ, Wu Q, Li Y, Yang J, Pan H, Ouyang X, Qiu W, Wu K, Xiong J, Dai G, Liang H, Hu C, Zhang J, Tao M, Yao Q, Wang J, Chen J, Eggleton SP, Liu T. Qin S, et al. Among authors: qiu w. J Clin Oncol. 2018 Oct 20;36(30):3031-3039. doi: 10.1200/JCO.2018.78.3183. Epub 2018 Sep 10. J Clin Oncol. 2018. PMID: 30199311 Free PMC article. Clinical Trial.
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, Fan Q, Xu Q, Ma Y, Wang G, Guo J, Su W, Fan S, Tan P, Wang Y, Luo Y, Zhou H, Li J. Guo Y, et al. Among authors: qiu w. Eur J Cancer. 2023 Mar;181:26-37. doi: 10.1016/j.ejca.2022.12.004. Epub 2022 Dec 13. Eur J Cancer. 2023. PMID: 36628898 Free article. Clinical Trial.
Repurposing FBP1: dephosphorylating IκBα to suppress NFκB.
Zhang G, Tao J, Lin L, Qiu W, Lu Z. Zhang G, et al. Among authors: qiu w. Cell Res. 2023 Jun;33(6):419-420. doi: 10.1038/s41422-023-00785-4. Cell Res. 2023. PMID: 36828939 Free PMC article. No abstract available.
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.
Wang J, Zhang B, Peng L, Liu X, Sun J, Su C, Wang H, Zhao Z, Si L, Duan J, Zhang H, Li M, Zhu B, Zhang L, Li J, Guo J, Luo R, Qiu W, Ye D, Chu Q, Cui J, Dong X, Fan Y, Gao Q, Guo Y, He Z, Li W, Lin G, Liu L, Liu Y, Qin H, Ren S, Ren X, Wang Y, Xue J, Yang Y, Yang Z, Yue L, Zhan X, Zhang J, Ma J, Qin S, Wang B. Wang J, et al. Among authors: qiu w. Ther Adv Med Oncol. 2023 Jul 16;15:17588359231187205. doi: 10.1177/17588359231187205. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37484525 Free PMC article. Review.
Base editing of the mutated TERT promoter inhibits liver tumor growth.
Zhao G, Ma Q, Yang H, Jiang H, Xu Q, Luo S, Meng Z, Liu J, Zhu L, Lin Q, Li M, Fang J, Ma L, Qiu W, Mao Z, Lu Z. Zhao G, et al. Among authors: qiu w. Hepatology. 2024 Jun 1;79(6):1310-1323. doi: 10.1097/HEP.0000000000000700. Epub 2023 Nov 28. Hepatology. 2024. PMID: 38016019
76 results